Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Autor: Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, Aloisi E

Publikováno v: Clinical, Cosmetic and Investigational Dermatology, Vol Volume 16, Pp 3561-3574 (2023)

Filomena Russo,1 Marco Galluzzo,2,3 Luca Stingeni,4 Severino Persechino,5 Leonardo Zichichi,6 Andrea Conti,7 Claudia Giofrè,8 Valentina Dini,9 Martina Vispi,10 Laura Atzori,11 Angelo Cattaneo,12 Aurora Parodi,13 Federico Bardazzi,14 Giuseppe Stinco,

Externí odkaz: https://doaj.org/article/115768c008944ac5b86654ed48f517a0

Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study

Autor: Stingeni L, Malara G, Conti A, Di Costanzo L, Carrera CG, Burlando M, Malagoli P, Musumeci ML, Bardazzi F, Brazzelli V, Amerio P, De Simone C, Trevisini S, Balato A, Megna M, Loconsole F, De Felice C, Bartezaghi M, Rausa A, Aloisi E, Orsenigo R, Costanzo A

Publikováno v: Clinical, Cosmetic and Investigational Dermatology, Vol Volume 16, Pp 27-38 (2023)

Luca Stingeni,1 Giovanna Malara,2,3 Andrea Conti,4 Luisa Di Costanzo,5 Carlo Giovanni Carrera,6 Martina Burlando,7 Piergiorgio Malagoli,8 Maria Letizia Musumeci,9 Federico Bardazzi,10 Valeria Brazzelli,11 Paolo Amerio,12 Clara De Simone,13,14 Sara Tr

Externí odkaz: https://doaj.org/article/a7ae5b045dc04385a0f61e76b2ee8b81

Effect of secukinumab on perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study

Autor: Talamonti, M, Malara, G, Natalini, Y, Bardazzi, F, Conti, A, Chiricozzi, A, Mugheddu, C, Gisondi, P, Piaserico, S, Pagnanelli, G, Amerio, P, Potenza, C, Cantoresi, F, M Concetta Fargnoli, Balato, A, Loconsole, F, Offidani, A, Bonifati, C, Prignano, F, Bartezaghi, M, Rausa, A, Aloisi, E, Orsenigo, R, Costanzo, A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3667::672f4e3ea4cac4976c80300005971aba
http://hdl.handle.net/2108/260569

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice

Autor: Aloisi E., Le Corf K., Dupuis J., Zhang P., Ginger M., Labrousse V., Spatuzza M., Georg Haberl M., Costa L., Shigemoto R., Tappe-Theodor A., Drago F., Vincenzo Piazza P., Mulle C., Groc L., Ciranna L., Catania M.V., Frick A.

Publikováno v: Nature communications 8 (2017): 1–14. doi:10.1038/s41467-017-01191-2
info:cnr-pdr/source/autori:Aloisi E.; Le Corf K.; Dupuis J.; Zhang P.; Ginger M.; Labrousse V.; Spatuzza M.; Georg Haberl M.; Costa L.; Shigemoto R.; Tappe-Theodor A.; Drago F.; Vincenzo Piazza P.; Mulle C.; Groc L.; Ciranna L.; Catania M.V.; Frick A./titolo:Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice/doi:10.1038%2Fs41467-017-01191-2/rivista:Nature communications/anno:2017/pagina_da:1/pagina_a:14/intervallo_pagine:1–14/volume:8

Metabotropic glutamate receptor subtype 5 (mGluR5) is crucially implicated in the pathophysiology of Fragile X Syndrome (FXS); however, its dysfunction at the sub-cellular level, and related synaptic and cognitive phenotypes are unexplored. Here, we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::00882e94ee9aaa3f604dc2c8403e2495
https://publications.cnr.it/doc/386745